Related Experiment Video
Updated: Oct 15, 2025

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
[stent thrombosis : A won battle ? (data from the France PCI registry)]
G Rangé1, R Hakim1, C Saint Etienne2
1Hôpitaux de Chartres, Service de Cardiologie, 4 rue Claude Bernard 28630 Le Coudray.
Insights
The incidence of stent thrombosis (ST) decreased since 2014 but remains high, with identified risk factors. Despite advancements, ST continues to have a significant impact on patient mortality.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Clinical Research
Background:
- Stent thrombosis (ST) remains a serious complication following coronary angioplasty.
- Understanding the incidence, risk factors, and outcomes of ST is crucial for improving patient care.
Purpose of the Study:
- To assess the 1-year incidence, identify risk factors, and evaluate the prognosis of definite stent thrombosis (ST).
- To analyze trends in ST rates within a large, multicenter prospective registry in France.
Main Methods:
- A prospective registry included 35,435 patients undergoing coronary angioplasty with stent implantation from 2014 to 2019.
- Patients were categorized into ST and control groups to compare outcomes and risk factors.
Main Results:
- The overall 1-year ST incidence was 0.72%, decreasing in acute coronary syndromes but not chronic ones.
- Identified risk factors for ST include younger age, diabetes, renal failure, previous angioplasty, LV dysfunction, longer stent length, and lower pre-procedure TIMI flow.
- 1-year mortality was significantly higher in the ST group (19.14%) compared to the control group (5.82%).
Conclusions:
- While the incidence of ST has decreased, it has plateaued, indicating a persistent challenge.
- Risk factors for ST are well-defined, but its high associated mortality necessitates continued efforts in prevention and management.
Goal:
The aim of the study is to assess the incidence, risk factors and prognosis of definite stent thrombosis (ST) at 1 year in the France PCI multicenter prospective registry.
Patients And Methods:
Only patients who underwent coronary angioplasty with at least one stent implantation between 1st January 2014 and 31 December 2019 were included. The population was separated into 2 groups: the "ST" group with stent thrombosis and the "control" group without stent thrombosis.
Results:
35,435 patients were included. 256 patients (0.72%) presented a ST at 1 year. The rate of ST decreased significantly in acute coronary syndrome (1.5% in 2014 vs. 0.73% in 2019; p = 0.05) but not in chronic coronary syndrome (0.46% in 2014 vs 0.40%; p = 0.98). The risk factors are young age (65.8 years vs 68.2; p = 0.002), clinical context (35.27% vs 16.68%; p = 0.0001), diabetes (35.2 % vs 26.4%; p = 0.002), renal failure (11.7% vs 8%; p = 0.009) and history of coronary angioplasty (28.63% vs 21.86%; p = 0.009) and peripheral arterial disease (14.5% vs 10.1%; p = 0.021), LV dysfunction (37% vs 27.5%; p = 0.003), mean length (39.6 mm vs 31, 7mm; p <0.0001) and the mean number of stents per procedure (1.9 vs 1.6; p <0.0001), a TIMI flow ≤1 pre procedure (21.5% vs 12.4%; p <0.0001) and an intrastent restenosis (11% vs 6%; p <0.0001). The 1-year mortality of the ST group was significantly higher than that of the control group (19.14% vs 5.82%; p <0.0001).
Conclusion:
Since 2014, the incidence of ST at 1 year has been decreasing but remains stuck at a floor level of 0.54% in 2019. The battle for ST seems to have been partly won and its risk factors well identified, but its mortality is still high.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease V: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

